TuHURA Biosciences (NASDAQ:HURA) Stock Keeps Buy Rating at HC Wainwright

TuHURA Biosciences (NASDAQ:HURA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright‘s price target would suggest a potential upside of 375.96% from the stock’s current price.

HURA has been the topic of a number of other research reports. Citizens Jmp restated a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a report on Tuesday, August 18th. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Price Performance

Shares of NASDAQ HURA traded up $0.06 during midday trading on Tuesday, reaching $2.10. The company’s stock had a trading volume of 369,609 shares, compared to its average volume of 876,234. The company has a current ratio of 0.18, a quick ratio of 0.18 and a debt-to-equity ratio of 0.20. The company has a 50 day moving average price of $2.04 and a 200 day moving average price of $1.93. TuHURA Biosciences has a one year low of $0.41 and a one year high of $3.43. The company has a market cap of $133.90 million, a price-to-earnings ratio of -3.89 and a beta of -0.21.

TuHURA Biosciences (NASDAQ:HURA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts expect that TuHURA Biosciences will post -0.55 EPS for the current year.

Institutional Trading of TuHURA Biosciences

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in TuHURA Biosciences in the second quarter worth approximately $1,615,000. Bank of New York Mellon Corp bought a new stake in shares of TuHURA Biosciences during the 2nd quarter worth $285,000. Apollon Wealth Management LLC boosted its holdings in shares of TuHURA Biosciences by 17.7% during the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock worth $283,000 after buying an additional 23,717 shares during the period. Cetera Investment Advisers acquired a new position in TuHURA Biosciences during the 1st quarter valued at $251,000. Finally, WealthShield Partners LLC acquired a new position in TuHURA Biosciences during the 2nd quarter valued at $214,000. 0.62% of the stock is owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.